145 related articles for article (PubMed ID: 26894389)
1. Enantioselective synthesis of adamantylalanine and carboranylalanine and their incorporation into the proteasome inhibitor bortezomib.
de Bruin G; Mock ED; Hoogendoorn S; van den Nieuwendijk AM; Mazurek J; van der Marel GA; Florea BI; Overkleeft HS
Chem Commun (Camb); 2016 Mar; 52(21):4064-7. PubMed ID: 26894389
[TBL] [Abstract][Full Text] [Related]
2. The proteostasis guardian HSF1 directs the transcription of its paralog and interactor HSF2 during proteasome dysfunction.
Santopolo S; Riccio A; Rossi A; Santoro MG
Cell Mol Life Sci; 2021 Feb; 78(3):1113-1129. PubMed ID: 32607595
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel 20S proteasome inhibitors by rational topology-based scaffold hopping of bortezomib.
Xu Y; Yang X; Chen Y; Chen H; Sun H; Li W; Xie Q; Yu L; Shao L
Bioorg Med Chem Lett; 2018 Jul; 28(12):2148-2152. PubMed ID: 29773504
[TBL] [Abstract][Full Text] [Related]
4. The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.
Schrader J; Henneberg F; Mata RA; Tittmann K; Schneider TR; Stark H; Bourenkov G; Chari A
Science; 2016 Aug; 353(6299):594-8. PubMed ID: 27493187
[TBL] [Abstract][Full Text] [Related]
5. Development of peptidomimetic boronates as proteasome inhibitors.
Micale N; Ettari R; Lavecchia A; Di Giovanni C; Scarbaci K; Troiano V; Grasso S; Novellino E; Schirmeister T; Zappalà M
Eur J Med Chem; 2013 Jun; 64():23-34. PubMed ID: 23639651
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of the boron adducts of the proteasome inhibitor bortezomib with epigallocatechin-3-gallate and related polyphenols.
Glynn SJ; Gaffney KJ; Sainz MA; Louie SG; Petasis NA
Org Biomol Chem; 2015 Apr; 13(13):3887-99. PubMed ID: 25669488
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib Inhibits Open Configurations of the 20S Proteasome.
Henderson LW; Gautam AKS; Sharon EM; Johnson CR; Rommel NG; Anthony AJ; Russell DH; Jarrold MF; Matouschek A; Clemmer DE
J Am Soc Mass Spectrom; 2024 Jun; 35(6):1063-1068. PubMed ID: 38748611
[TBL] [Abstract][Full Text] [Related]
8. Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
Xi J; Zhuang R; Kong L; He R; Zhu H; Zhang J
Eur J Med Chem; 2019 Nov; 182():111646. PubMed ID: 31521028
[TBL] [Abstract][Full Text] [Related]
9. Catalytic asymmetric synthesis of α-methyl-p-boronophenylalanine.
Harada S; Kajihara R; Muramoto R; Jutabha P; Anzai N; Nemoto T
Bioorg Med Chem Lett; 2018 Jun; 28(10):1915-1918. PubMed ID: 29655983
[TBL] [Abstract][Full Text] [Related]
10. Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors.
Liu H; Wu J; Ge Y; Li A; Li J; Liu Z; Xu Y; Xu Q; Li Y
Bioorg Med Chem; 2018 Mar; 26(5):1050-1061. PubMed ID: 29426629
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibitors.
Cvek B
Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
[TBL] [Abstract][Full Text] [Related]
12. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.
Troiano V; Scarbaci K; Ettari R; Micale N; Cerchia C; Pinto A; Schirmeister T; Novellino E; Grasso S; Lavecchia A; Zappalà M
Eur J Med Chem; 2014 Aug; 83():1-14. PubMed ID: 24946214
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine.
Jorda R; Dušek J; Řezníčková E; Pauk K; Magar PP; Imramovský A; Kryštof V
Eur J Med Chem; 2017 Jul; 135():142-158. PubMed ID: 28441582
[TBL] [Abstract][Full Text] [Related]
14. Electrochemical assay for 20S proteasome activity and inhibition with anti-cancer drugs.
Henriques de Jesus CS; Chiorcea-Paquim AM; Barsan MM; Diculescu VC
Talanta; 2019 Jul; 199():32-39. PubMed ID: 30952265
[TBL] [Abstract][Full Text] [Related]
15. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
Berkers CR; Leestemaker Y; Schuurman KG; Ruggeri B; Jones-Bolin S; Williams M; Ovaa H
Mol Pharm; 2012 May; 9(5):1126-35. PubMed ID: 22432738
[TBL] [Abstract][Full Text] [Related]
16. (Immuno)proteasomes as therapeutic target in acute leukemia.
Cloos J; Roeten MS; Franke NE; van Meerloo J; Zweegman S; Kaspers GJ; Jansen G
Cancer Metastasis Rev; 2017 Dec; 36(4):599-615. PubMed ID: 29071527
[TBL] [Abstract][Full Text] [Related]
17. Design of proteasome inhibitors with oral efficacy in vivo against
Xie SC; Metcalfe RD; Mizutani H; Puhalovich T; Hanssen E; Morton CJ; Du Y; Dogovski C; Huang SC; Ciavarri J; Hales P; Griffin RJ; Cohen LH; Chuang BC; Wittlin S; Deni I; Yeo T; Ward KE; Barry DC; Liu B; Gillett DL; Crespo-Fernandez BF; Ottilie S; Mittal N; Churchyard A; Ferguson D; Aguiar ACC; Guido RVC; Baum J; Hanson KK; Winzeler EA; Gamo FJ; Fidock DA; Baud D; Parker MW; Brand S; Dick LR; Griffin MDW; Gould AE; Tilley L
Proc Natl Acad Sci U S A; 2021 Sep; 118(39):. PubMed ID: 34548400
[TBL] [Abstract][Full Text] [Related]
18. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
[TBL] [Abstract][Full Text] [Related]
19. Boron chemicals in diagnosis and therapeutics.
Das BC; Thapa P; Karki R; Schinke C; Das S; Kambhampati S; Banerjee SK; Van Veldhuizen P; Verma A; Weiss LM; Evans T
Future Med Chem; 2013 Apr; 5(6):653-76. PubMed ID: 23617429
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
Ge Y; Li A; Wu J; Feng H; Wang L; Liu H; Xu Y; Xu Q; Zhao L; Li Y
Eur J Med Chem; 2017 Mar; 128():180-191. PubMed ID: 28182990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
